Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Thermo Fisher Scientific (TMO) Stock Forecast & Price Target

Thermo Fisher Scientific logo
$673.96 -2.58 (-0.38%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$676.39 +2.42 (+0.36%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
4
Buy
20

Based on 25 Wall Street analysts who have issued ratings for Thermo Fisher Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 1 has given a sell rating, 4 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for TMO.

Consensus Price Target

$681.00
1.04% Upside
According to the 25 analysts' twelve-month price targets for Thermo Fisher Scientific, the average price target is $681.00. The highest price target for TMO is $810.00, while the lowest price target for TMO is $520.00. The average price target represents a forecasted upside of 1.04% from the current price of $673.97.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TMO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Thermo Fisher Scientific and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMO Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
18 Buy rating(s)
17 Buy rating(s)
17 Buy rating(s)
18 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$681.00$624.64$613.05$595.75
Forecasted Upside1.04% Upside-7.40% Downside9.71% Upside3.96% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

TMO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Thermo Fisher Scientific Stock vs. The Competition

TypeThermo Fisher ScientificHealthcare CompaniesBroader Market
Consensus Rating Score
2.84
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside1.04% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent TMO News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Patrick Donnelly
4 of 5 stars
Boost TargetBuy$685.00 ➝ $800.00+18.33%
10/23/2026
DZ Bank AG logo
DZ Bank
5 of 5 stars
 DowngradeStrong-Buy ➝ Hold
10/22/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Doug Schenkel
Doug Schenkel
Not Rated
Reiterated RatingBuy$800.00+16.54%
10/22/2026Boost TargetSector Perform$580.00 ➝ $730.00+6.12%
10/22/2026Boost TargetOverweight$750.00 ➝ $775.00+11.67%
10/22/2026Boost TargetBuy$760.00 ➝ $810.00+18.52%
10/22/2026Boost TargetBuy$650.00 ➝ $775.00+11.67%
10/22/2026Boost TargetOutperform$723.00 ➝ $756.00+8.94%
10/15/2026 Initiated CoverageBuy
10/12/2026Boost TargetOverweight$650.00 ➝ $730.00+11.10%
10/8/2026 UpgradeHold (C+) ➝ Buy (B-)
9/25/2026 Reiterated RatingBuy$720.00+8.08%
9/9/2026Initiated CoverageHold ➝ Overweight
9/9/2026 Initiated CoverageOutperform
9/9/2026 DowngradeMarket Perform
9/9/2026DowngradeOverweight ➝ Underweight
9/3/2026Initiated CoverageOutperformC$748.00
9/1/2026UpgradeHold ➝ Strong-Buy
7/23/2026 Reiterated RatingBuy$630.00+9.86%
7/6/2026 Set Target$570.00+11.06%
6/26/2026Initiated CoverageMarket Perform$520.00+2.73%
6/2/2026Initiated CoverageOutperform$535.00+8.48%
5/26/2026 Reiterated RatingOverweight
12/9/2025Initiated CoverageBuy$685.00+20.63%
10/29/2025Boost TargetBuy$580.00 ➝ $610.00+6.91%
10/22/2025Boost TargetOutperform$545.00 ➝ $580.00+2.04%
10/9/2025Boost TargetOverweight$600.00 ➝ $650.00+21.11%
10/8/2025 Set Target$580.00+7.50%
8/18/2025Initiated CoverageOutperform
7/24/2025Reiterated RatingOutperform$525.00 ➝ $535.00+11.59%
12/13/2024 Lower TargetBuy$675.00 ➝ $660.00+26.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:40 PM ET.


Should I Buy Thermo Fisher Scientific Stock? TMO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Thermo Fisher Scientific pros and cons to contact@marketbeat.com.

Thermo Fisher Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

  • Thermo Fisher Scientific Inc. recently reported third-quarter revenue of $12.14 billion, which was up 9.1% year over year, while adjusted earnings per share of $6.68 exceeded the consensus estimate of $6.40, demonstrating strong operational performance and the ability to beat market expectations.
  • Management raised its full-year 2026 revenue-growth and earnings outlook following the recent earnings release, signaling confidence in the company's trajectory and suggesting that the current recovery across clinical research, bioproduction, and laboratory products is sustainable.
  • Analysts have shown strong bullish sentiment, with TD Cowen raising its price target to $810 and Stifel Nicolaus lifting its target to $775, reflecting a consensus view that the stock is undervalued relative to its fundamental improvements and industry growth potential.
  • The company is positioned to benefit from long-term industry growth, such as the peptide-synthesis market which is projected to expand from $0.98 billion in 2026 to $1.54 billion by 2031, driven by the development of GLP-1 drugs and increased pharmaceutical activity.
  • Thermo Fisher Scientific Inc. currently trades at a stock price of $673.97, which is below the average analyst price target of $675.52 and significantly lower than the highest individual target of $810, suggesting potential upside for investors entering the position now.

Thermo Fisher Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

  • Despite the strong earnings report, the stock price reaction has been muted, with the share price only up about 1% after the release, indicating that investors may be demanding clearer evidence that the end-market recovery can justify the stock's elevated earnings multiple.
  • Heavy put-option buying, including activity roughly 52% above average, suggests that some traders are hedging against a potential pullback or positioning defensively, signaling caution among market participants regarding the stock's near-term direction.
  • Corporate insiders have been selling shares, with the CEO Marc N. Casper selling 10,000 shares at an average price of $629.27 in August 2026, and other executives like COO Gianluca Pettiti also reducing their holdings, which can be interpreted as a lack of confidence in the current valuation.
  • The company trades at a price-to-earnings ratio of 36.25, which is a premium valuation that may leave little room for error if the recovery in life sciences markets slows down or if macroeconomic conditions deteriorate.
  • Short interest has increased slightly, with shares shorted rising to 5,408,135 in the most recent period, indicating that some investors are betting against the stock's performance, which could create downward pressure on the share price.

TMO Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Thermo Fisher Scientific is $681.00, with a high forecast of $810.00 and a low forecast of $520.00.

25 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Thermo Fisher Scientific in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TMO shares.

According to analysts, Thermo Fisher Scientific's stock has a predicted upside of 1.04% based on their 12-month stock forecasts.

Over the previous 90 days, Thermo Fisher Scientific's stock had 5 downgrades and 4 upgrades by analysts.

Analysts like Thermo Fisher Scientific more than other "healthcare" companies. The consensus rating for Thermo Fisher Scientific is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how TMO compares to other companies.


MarketBeat monitors more than a dozen sources for Thermo Fisher Scientific analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners